Westpac Banking Corp Has $7.47 Million Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Share on StockTwits

Westpac Banking Corp lessened its stake in Repligen Co. (NASDAQ:RGEN) by 8.4% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 86,885 shares of the biotechnology company’s stock after selling 8,000 shares during the quarter. Westpac Banking Corp’s holdings in Repligen were worth $7,468,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in RGEN. Huntington National Bank bought a new stake in Repligen in the first quarter worth approximately $25,000. Royce & Associates LP grew its position in Repligen by 40.6% in the first quarter. Royce & Associates LP now owns 502 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 145 shares in the last quarter. Mascoma Wealth Management LLC bought a new stake in Repligen in the first quarter worth approximately $41,000. Private Capital Group LLC grew its position in Repligen by 675.3% in the first quarter. Private Capital Group LLC now owns 721 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 628 shares in the last quarter. Finally, South Dakota Investment Council bought a new stake in Repligen in the first quarter worth approximately $83,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

Shares of NASDAQ RGEN traded up $1.46 during trading hours on Thursday, hitting $90.27. 4,188 shares of the stock were exchanged, compared to its average volume of 776,547. The company has a quick ratio of 1.88, a current ratio of 2.25 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average is $88.42. The stock has a market cap of $4.64 billion, a price-to-earnings ratio of 124.14, a P/E/G ratio of 5.28 and a beta of 1.08. Repligen Co. has a one year low of $48.26 and a one year high of $99.25.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, August 1st. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.25 by $0.06. The business had revenue of $70.70 million during the quarter, compared to the consensus estimate of $65.47 million. Repligen had a net margin of 11.42% and a return on equity of 6.92%. Repligen’s quarterly revenue was up 48.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.14 EPS. On average, analysts anticipate that Repligen Co. will post 0.97 EPS for the current year.

In other Repligen news, Director Karen A. Dawes sold 1,295 shares of the stock in a transaction on Monday, June 17th. The shares were sold at an average price of $77.35, for a total value of $100,168.25. Following the completion of the sale, the director now directly owns 118,329 shares of the company’s stock, valued at approximately $9,152,748.15. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Glenn L. Md Cooper sold 5,000 shares of the stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $66.94, for a total transaction of $334,700.00. Following the completion of the sale, the director now directly owns 35,975 shares of the company’s stock, valued at $2,408,166.50. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by corporate insiders.

Several analysts have commented on RGEN shares. Craig Hallum boosted their target price on shares of Repligen from $80.00 to $108.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. BidaskClub raised shares of Repligen from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 27th. HC Wainwright reissued a “buy” rating and issued a $110.00 target price on shares of Repligen in a research report on Monday. Zacks Investment Research downgraded shares of Repligen from a “buy” rating to a “hold” rating in a research report on Wednesday, August 7th. Finally, ValuEngine downgraded shares of Repligen from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 1st. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $97.50.

Repligen Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Recommended Story: What are convertible shares? 

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.